





Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

May 31, 2016

M/S. Meril Endo Surgery Private Limited Mr. Umesh Sharma Deputy General Manager - Quality Assurance 3fl, E1-e3, Meril Park, Survey No. 135/2/b & 174/2, Muktanand Marg Chala, Vapi, Gujaret 396191 INDIA

Re: K160623

Trade/Device Name: Filasilk - Natural Non-absorbable Silk Surgical Suture, Filamide -

Non Absorbable Polyamide Surgical Sutures, Mericron XI - Non Absorbable Polyester Surgical Suture, Filaprop - Non Absorbable

Polypropylene Surgical Suture

Regulation Number: 21 CFR 878.5030

Regulation Name: Natural Nonabsorbable Silk Surgical Suture

Regulatory Class: Class II

Product Code: GAP, GAR, GAT, GAW

Dated: March 1, 2016 Received: March 4, 2016

Dear Mr. Sharma:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Jennifer R. Stevenson -A

For Binita S. Ashar, M.D., M.B.A., F.A.C.S.
Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known)
K160623
Device Name FILAMIDE
Indications for Use (Describe) FILAMIDE is intended for use as non-absorbable sutures in general soft tissue approximation including skin tissue closure and/or ligation in cardiac, vascular and ophthalmic procedures.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known)
K160623
Device Name FILAPROP
Indications for Use (Describe) FILAPROP sutures are intended for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

Device Name FILASILK Indications for Use (Describe) FILASILK is intended for use as non-absorbable sutures in general soft tissue approximation and/or ligation including usin cardiac, vascular and ophthalmic procedures.	se
FILASILK Indications for Use (Describe) FILASILK is intended for use as non-absorbable sutures in general soft tissue approximation and/or ligation including use	se
Indications for Use (Describe) FILASILK is intended for use as non-absorbable sutures in general soft tissue approximation and/or ligation including us	se .
FILASILK is intended for use as non-absorbable sutures in general soft tissue approximation and/or ligation including us	se
FILASILK is intended for use as non-absorbable sutures in general soft tissue approximation and/or ligation including us	se
FILASILK is intended for use as non-absorbable sutures in general soft tissue approximation and/or ligation including us	se
	se
in cardiac, vascular and ophulannic procedures.	
Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)	

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known)
K160623
Device Name MERICRON XL
Indications for Use (Describe) MERICRON XL suture is intended for use in general soft tissue approximation and/or ligation including cardiovascular surgery, neurosurgery and ophthalmic procedures.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

510(k) Summary

I. Submitter

M/s. Meril Endo Surgery Private Limited

Third Floor, E1 – E3, Meril Park,

Survey No. 135/2/B & 174/2, Muktanand Marg,

Chala, Vapi – 396191 Gujarat, India.

Tel. No: +91-260-3052100, Fax: +91-260-3052125

Web site: www.merillife.com

E-mail: umesh.sharma@merillife.com

Contact Person: Umesh Sharma Date Prepared: Feb 26, 2016

II. Device

Sr. No.	Trade / Proprietary Name	Common Name	Classification	Regulatory Class	Product Code	Regulation Number	Review Panel
1.	FILASILK TM Natural Non- absorbable Silk Surgical Suture	Natural Non- absorbable Silk Surgical Suture	Suture, Non absorbable, Silk	II	GAP	878.5030	General & Plastic Surgery
2.	FILAMIDE TM Non Absorbable Polyamide Surgical Sutures	Non- absorbable Polyamide Surgical Suture	Suture, Non absorbable, Synthetic, Polyamide	II	GAR	878.5020	General & Plastic Surgery
3.	MERICRON XL TM Non Absorbable Polyester Surgical Suture	Non absorbable Poly (Ethylene Terephthal ate) Suture	Suture, Non absorbable, Synthetic, Poly (Ethylene Terephthalate)	II	GAT	878.5000	General & Plastic Surgery
4.	Non Absorbable Polypropylene Surgical Suture	Non- absorbable Polypropyl ene Surgical Suture	Suture, Non absorbable, Synthetic, Polypropylene	II	GAW	878.5010	General & Plastic Surgery

III. Predicate Device

Sr. No.	Meril's Suture Trade /	Predicate	Predicate				
	Proprietary Name	Device Name	me Device				
			510(k) No.				
1.	FILASILK™ Natural Non-	TRUSILK	K041514				
	absorbable Silk Surgical Suture						
2.	FILAMIDE™ Non Absorbable	TRULON	K041510				
	Polyamide Surgical Sutures						
3.	MERICRON XL™ Non	TRUBOND	K041512				
	Absorbable Polyester Surgical						
	Suture						
4.	FILAPROP™ Non Absorbable	PROLENE	K133356				
	Polypropylene Surgical Suture						

IV. Device Description

a. FILASILK[™] Natural Non-absorbable Silk Surgical Suture

FILASILK[™] silk suture is a non-absorbable, sterile, surgical suture composed of an organic protein called fibroin. This protein is derived from the domesticated species *Bombyx mori* (*B. mori*) of the family Bombycidae. FILASILK[™] sutures are processed to remove the natural waxes and gums. FILASILK[™] suture is available undyed or dyed black with Logwood extract and coated with bees wax. FILASILK[™] suture meets requirements established by the United States Pharmacopoeia (U.S.P.) for non-absorbable surgical suture.

b. FILAMIDE[™] Non Absorbable Polyamide Surgical Sutures

FILAMIDETM suture is a non-absorbable, sterile, synthetic, monofilament surgical suture composed of polyamide 6 [(NH-CO-(CH₂)₅]_n and Polyamide 6,6 (NH(CH₂)₆-NH-CO-(CH₂)₄-CO)_n. FILAMIDETM sutures are dyed with Logwood extract. Available in a broad range of suture sizes and lengths, FILAMIDETM is either non-needled or attached to standard stainless steel needles of varying types and sizes.

c. MERICRON XL[™] Non Absorbable Polyester Surgical Suture

MERICRON XL[™] suture is a coated, braided, non-absorbable sterile surgical suture composed of poly (ethylene terephthalate). The empirical molecular formula of the polymer is (C₁₀H₈O₄)_n. The suture is coated with bees wax which acts as a lubricant to mechanically improve the ease of passage through tissue and the overall handling quality of the suture.

MERICRON XL[™] is available undyed or dyed green with D & C Green No.6. MERICRON XL[™] is available in a range of gauge sizes and lengths, or attached to standard stainless steel needles of various types and sizes

d. FILAPROP[™] Non Absorbable Polypropylene Surgical Suture

FILAPROPTM suture is a monofilament, synthetic non-absorbable, sterile surgical suture composed of an isotactic crystalline stereoisomer of polypropylene, a synthetic linear polyolefin. The molecular formula of polypropylene is $(C_3H_6)_{n.}$ **FILAPROP**TM sutures are dyed with phthalocyanine blue.

FILAPROP[™] is available in a range of gauge sizes and lengths attached to standard stainless steel needles of various types and sizes

V. Intended Use

a. FILASILK[™] Natural Non-absorbable Silk Surgical Suture

FILASILK[™] is intended for use as non-absorbable sutures in general soft tissue approximation and/or ligation including use in cardiac, vascular and ophthalmic procedures.

b. FILAMIDE[™] Non Absorbable Polyamide Surgical Sutures

FILAMIDE™ Non-absorbable Polyamide Surgical suture is indicated for use in soft tissue approximation and/ or ligation, including use in cardiovascular, ophthalmic and neurological procedures.

c. MERICRON XL[™] Non Absorbable Polyester Surgical Suture

MERICRON XL[™] suture is intended for use in general soft tissue approximation and/or ligation including cardiovascular surgery, neurological and ophthalmic procedures.

d. FILAPROP[™] Non Absorbable Polypropylene Surgical Suture

FILAPROP™ sutures are intended for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.

VI. Substantial Equivalence

The device design, material of construction, performance, packaging and intended uses are similar to the predicate device. Substantial equivalence is conducted based on the following parameters:

- 1. Product description
- 2. Intended use
- 3. Suture Size
- 4. Colorant Used Dye / Un-dyed
- 5. Suture Coating
- 6. Single use
- 7. Sterilisation method

- 8. Packaging
- 9. Label Claim
- 10. Performance
 - a. Diameter USP <861>
 - b. Tensile strength USP <88I>
 - c. Needle attachment USP <871>
 - d. Suture Length
- 11. Labeling and Instructions for use (IFU)

VII. Performance Data

The Surgical Suture was subjected to the performance testing as per USP requirements. The safety and effectiveness of the Surgical Suture has been evaluated for the following performance and safety requirements.

- 1. Diameter USP <861>
- 2. Tensile strength USP <88I>
- 3. Needle attachment USP <871>
- 4. Suture Length
- 5. Biocompatibility
 - a. In Vitro Cytotoxicity Study
 - b. Skin Sensitization Study
 - c. Intracutaneous Reactivity Test
 - d. Acute Systemic Toxicity Study
 - e. Sub Chronic Toxicity Study
 - f. Intramuscular Implantation Test
 - g. Bacterial Reverse Mutation Test
 - h. Mammalian Erythrocyte Micronucleus Test
 - i. In Vitro Hemolysis Test
 - j. Pyrogen Test

VIII. Conclusion

Meril's Surgical Sutures are composed of the same materials, as are the predicate devices and has the same design, as do the predicate.

The subject devices are offered with the same colorants as predicate devices i.e. Logwood extract black used in **FILASILK**[™] & **FILAMIDE**[™] is in accordance to 21 CFR 73.1410, D&C Green No. 6 used in **MERICRON** XL[™] is in accordance with 21 CFR 74.3206 & Phthalocyanine blue used in **FILAPROP**[™] is in accordance with 21 CFR 74. 3045).

Performance testing of the Meril sutures complies the USP requirements i.e. suture diameter, suture length, knot pull tensile strength, extractable color, suture-needle

attachment and sterility. However, **FILAMIDE™** & **FILAPROP™** may be slightly oversize in diameter to U.S.P. requirement for some suture sizes.